Project to focus on drug development for schizophrenia, depression

01/19/2010 | EurekAlert!

An international team of researchers, headed by H. Lundbeck A/S and King's College London, has formed the Novel Methods leading to New Medications in Depression and Schizophrenia, an academic-industry research tie-up that will focus on finding new ways to develop treatments for schizophrenia and depression. The project aims to develop new animal models for brain studies, as well as hardware and analysis methods that can be used in brain imaging, including MRI and PET.

View Full Article in:

EurekAlert!

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Food & Drug Associate
Confidential
Washington, D.C., DC